http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 08 Oct 2025 16:57:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Navidea+Biopharmaceuticals%2C+Inc.+Files+for+Bankruptcy/25436103.html <p> <i>Navidea Biopharmaceucitals, Inc. files for Bankruptcy</i> </p> <p> COLUMBUS, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it filed a voluntary petition for relief under Chapter 11, Subchapter V of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the “Court”) on October 1, 2025. </p><p> The filing is intended to enable the Company to pursue an orderly restructuring of its financial obligations while continuing limited operations to preserve value for creditors and stakeholders. The Company intends to use http://www.streetinsider.com/Press+Releases/Navidea+Biopharmaceuticals%2C+Inc.+Files+for+Bankruptcy/25436103.html Wed, 08 Oct 2025 16:57:00 -0400 NAVB http://www.streetinsider.com/Business+Wire/Navidea+Biopharmaceuticals%2C+Inc.+Files+for+Bankruptcy/25436103.html <p> <i>Navidea Biopharmaceucitals, Inc. files for Bankruptcy</i> </p> <p> COLUMBUS, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it filed a voluntary petition for relief under Chapter 11, Subchapter V of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the “Court”) on October 1, 2025. </p><p> The filing is intended to enable the Company to pursue an orderly restructuring of its financial obligations while continuing limited operations to preserve value for creditors and stakeholders. The Company intends to use http://www.streetinsider.com/Business+Wire/Navidea+Biopharmaceuticals%2C+Inc.+Files+for+Bankruptcy/25436103.html Wed, 08 Oct 2025 16:57:00 -0400 NAVB http://www.streetinsider.com/Corporate+News/Navidea+Biopharma+%28NAVB%29+Announces+Extension+of+Authority+to+Implement+a+Reverse+Stock+Split/24834152.html <p>Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the extension of its authority to implement a reverse stock split of its common stock at a ratio of up to 1-for-50,000 shares.</p><p> </p><p>The Company originally received shareholder approval to amend its Certificate of Incorporation to authorize a reverse stock split at a ratio of up to 1-for-50,000 at a special meeting held on July 8, 2024. That authorization, which was initially set to expire on July 8, 2025, has now been extended by two years http://www.streetinsider.com/Corporate+News/Navidea+Biopharma+%28NAVB%29+Announces+Extension+of+Authority+to+Implement+a+Reverse+Stock+Split/24834152.html Wed, 21 May 2025 14:52:33 -0400 NAVB http://www.streetinsider.com/Press+Releases/Navidea+Biopharmaceuticals%2C+Inc.+Announces+Extension+of+Authority+to+Implement+a+Reverse+Stock+Split/24834147.html <p> <i>Navidea Biopharmaceucitals, Inc. extends deadline to implement a reverse stock split</i> </p> <p> COLUMBUS, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the extension of its authority to implement a reverse stock split of its common stock at a ratio of up to 1-for-50,000 shares. </p><p> The Company originally received shareholder approval to amend its Certificate of Incorporation to authorize a reverse stock split at a ratio of up to 1-for-50,000 at a special meeting held on July 8, 2024. That authorization, which was http://www.streetinsider.com/Press+Releases/Navidea+Biopharmaceuticals%2C+Inc.+Announces+Extension+of+Authority+to+Implement+a+Reverse+Stock+Split/24834147.html Wed, 21 May 2025 14:52:00 -0400 NAVB O.00073497 http://www.streetinsider.com/Press+Releases/Navidea+Biopharmaceuticals%2C+Inc.+Announces+Extension+of+Authority+to+Implement+a+Reverse+Stock+Split/24834147.html <p> <i>Navidea Biopharmaceucitals, Inc. extends deadline to implement a reverse stock split</i> </p> <p> COLUMBUS, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the extension of its authority to implement a reverse stock split of its common stock at a ratio of up to 1-for-50,000 shares. </p><p> The Company originally received shareholder approval to amend its Certificate of Incorporation to authorize a reverse stock split at a ratio of up to 1-for-50,000 at a special meeting held on July 8, 2024. That authorization, which was http://www.streetinsider.com/Press+Releases/Navidea+Biopharmaceuticals%2C+Inc.+Announces+Extension+of+Authority+to+Implement+a+Reverse+Stock+Split/24834147.html Wed, 21 May 2025 14:52:00 -0400 NAVB O.00073497 http://www.streetinsider.com/Business+Wire/Navidea+Biopharmaceuticals%2C+Inc.+Announces+Extension+of+Authority+to+Implement+a+Reverse+Stock+Split/24834147.html <p> <i>Navidea Biopharmaceucitals, Inc. extends deadline to implement a reverse stock split</i> </p> <p> COLUMBUS, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the extension of its authority to implement a reverse stock split of its common stock at a ratio of up to 1-for-50,000 shares. </p><p> The Company originally received shareholder approval to amend its Certificate of Incorporation to authorize a reverse stock split at a ratio of up to 1-for-50,000 at a special meeting held on July 8, 2024. That authorization, which was http://www.streetinsider.com/Business+Wire/Navidea+Biopharmaceuticals%2C+Inc.+Announces+Extension+of+Authority+to+Implement+a+Reverse+Stock+Split/24834147.html Wed, 21 May 2025 14:52:00 -0400 NAVB O.00073497 http://www.streetinsider.com/Business+Wire/Navidea+Biopharmaceuticals%2C+Inc.+Announces+Extension+of+Authority+to+Implement+a+Reverse+Stock+Split/24834147.html <p> <i>Navidea Biopharmaceucitals, Inc. extends deadline to implement a reverse stock split</i> </p> <p> COLUMBUS, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the extension of its authority to implement a reverse stock split of its common stock at a ratio of up to 1-for-50,000 shares. </p><p> The Company originally received shareholder approval to amend its Certificate of Incorporation to authorize a reverse stock split at a ratio of up to 1-for-50,000 at a special meeting held on July 8, 2024. That authorization, which was http://www.streetinsider.com/Business+Wire/Navidea+Biopharmaceuticals%2C+Inc.+Announces+Extension+of+Authority+to+Implement+a+Reverse+Stock+Split/24834147.html Wed, 21 May 2025 14:52:00 -0400 NAVB O.00073497 http://www.streetinsider.com/Press+Releases/Navidea+Biopharmaceuticals+Announces+the+Extension+of+Plan+Designed+to+Protect+NOLs+and+Other+Tax+Assets/24576814.html <p> COLUMBUS, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”) today announced that its Board of Directors has elected to extend the Company’s Section 382 Rights Agreement (the “Section 382 Rights Plan”). Originally adopted on April 7, 2022, and set to expire on April 6, 2025, the plan has now been extended to April 7, 2027. </p><p> The Section 382 Rights Plan is designed to safeguard Navidea’s ability to utilize its net operating loss carryforwards (“NOLs”) and other tax assets. As of December 31, 2024, Navidea had approximately $170 million in U.S. federal NOLs and approximately $9 million in http://www.streetinsider.com/Press+Releases/Navidea+Biopharmaceuticals+Announces+the+Extension+of+Plan+Designed+to+Protect+NOLs+and+Other+Tax+Assets/24576814.html Mon, 31 Mar 2025 18:08:00 -0400 NAVB O.00073497 http://www.streetinsider.com/Press+Releases/Navidea+Biopharmaceuticals+Announces+the+Extension+of+Plan+Designed+to+Protect+NOLs+and+Other+Tax+Assets/24576814.html <p> COLUMBUS, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”) today announced that its Board of Directors has elected to extend the Company’s Section 382 Rights Agreement (the “Section 382 Rights Plan”). Originally adopted on April 7, 2022, and set to expire on April 6, 2025, the plan has now been extended to April 7, 2027. </p><p> The Section 382 Rights Plan is designed to safeguard Navidea’s ability to utilize its net operating loss carryforwards (“NOLs”) and other tax assets. As of December 31, 2024, Navidea had approximately $170 million in U.S. federal NOLs and approximately $9 million in http://www.streetinsider.com/Press+Releases/Navidea+Biopharmaceuticals+Announces+the+Extension+of+Plan+Designed+to+Protect+NOLs+and+Other+Tax+Assets/24576814.html Mon, 31 Mar 2025 18:08:00 -0400 NAVB O.00073497 http://www.streetinsider.com/Business+Wire/Navidea+Biopharmaceuticals+Announces+the+Extension+of+Plan+Designed+to+Protect+NOLs+and+Other+Tax+Assets/24576814.html <p> COLUMBUS, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”) today announced that its Board of Directors has elected to extend the Company’s Section 382 Rights Agreement (the “Section 382 Rights Plan”). Originally adopted on April 7, 2022, and set to expire on April 6, 2025, the plan has now been extended to April 7, 2027. </p><p> The Section 382 Rights Plan is designed to safeguard Navidea’s ability to utilize its net operating loss carryforwards (“NOLs”) and other tax assets. As of December 31, 2024, Navidea had approximately $170 million in U.S. federal NOLs and approximately $9 million in http://www.streetinsider.com/Business+Wire/Navidea+Biopharmaceuticals+Announces+the+Extension+of+Plan+Designed+to+Protect+NOLs+and+Other+Tax+Assets/24576814.html Mon, 31 Mar 2025 18:08:00 -0400 NAVB O.00073497 http://www.streetinsider.com/Business+Wire/Navidea+Biopharmaceuticals+Announces+the+Extension+of+Plan+Designed+to+Protect+NOLs+and+Other+Tax+Assets/24576814.html <p> COLUMBUS, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”) today announced that its Board of Directors has elected to extend the Company’s Section 382 Rights Agreement (the “Section 382 Rights Plan”). Originally adopted on April 7, 2022, and set to expire on April 6, 2025, the plan has now been extended to April 7, 2027. </p><p> The Section 382 Rights Plan is designed to safeguard Navidea’s ability to utilize its net operating loss carryforwards (“NOLs”) and other tax assets. As of December 31, 2024, Navidea had approximately $170 million in U.S. federal NOLs and approximately $9 million in http://www.streetinsider.com/Business+Wire/Navidea+Biopharmaceuticals+Announces+the+Extension+of+Plan+Designed+to+Protect+NOLs+and+Other+Tax+Assets/24576814.html Mon, 31 Mar 2025 18:08:00 -0400 NAVB O.00073497 http://www.streetinsider.com/Press+Releases/Navidea+Biopharmaceuticals%2C+Inc.+Announces+Results+of+Exploratory+Analysis+Completed+on+July+2%2C+2024/23434105.html <p> <i>Navidea </i><i>Biopharmaceuticals</i><i>, Inc. has completed an exploratory analysis of its Rheumatoid Arthritis Program</i> </p> <p> COLUMBUS, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the Company’s pivotal NAV3-33 clinical trial titled “Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA)” (<a target="_blank" href="http://ClinicalTrials.gov">ClinicalTrials.gov</a> Identifier: NCT05246280) the “RA Trial.” </p><p> The purpose of the exploratory analysis was to optimize the diagnostic performance in http://www.streetinsider.com/Press+Releases/Navidea+Biopharmaceuticals%2C+Inc.+Announces+Results+of+Exploratory+Analysis+Completed+on+July+2%2C+2024/23434105.html Wed, 03 Jul 2024 16:30:00 -0400 NAVB O.00073497 http://www.streetinsider.com/Press+Releases/Navidea+Biopharmaceuticals%2C+Inc.+Announces+Results+of+Exploratory+Analysis+Completed+on+July+2%2C+2024/23434105.html <p> <i>Navidea </i><i>Biopharmaceuticals</i><i>, Inc. has completed an exploratory analysis of its Rheumatoid Arthritis Program</i> </p> <p> COLUMBUS, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the Company’s pivotal NAV3-33 clinical trial titled “Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA)” (<a target="_blank" href="http://ClinicalTrials.gov">ClinicalTrials.gov</a> Identifier: NCT05246280) the “RA Trial.” </p><p> The purpose of the exploratory analysis was to optimize the diagnostic performance in http://www.streetinsider.com/Press+Releases/Navidea+Biopharmaceuticals%2C+Inc.+Announces+Results+of+Exploratory+Analysis+Completed+on+July+2%2C+2024/23434105.html Wed, 03 Jul 2024 16:30:00 -0400 NAVB O.00073497 http://www.streetinsider.com/Business+Wire/Navidea+Biopharmaceuticals%2C+Inc.+Announces+Results+of+Exploratory+Analysis+Completed+on+July+2%2C+2024/23434105.html <p> <i>Navidea </i><i>Biopharmaceuticals</i><i>, Inc. has completed an exploratory analysis of its Rheumatoid Arthritis Program</i> </p> <p> COLUMBUS, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the Company’s pivotal NAV3-33 clinical trial titled “Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA)” (<a target="_blank" href="http://ClinicalTrials.gov">ClinicalTrials.gov</a> Identifier: NCT05246280) the “RA Trial.” </p><p> The purpose of the exploratory analysis was to optimize the diagnostic performance in http://www.streetinsider.com/Business+Wire/Navidea+Biopharmaceuticals%2C+Inc.+Announces+Results+of+Exploratory+Analysis+Completed+on+July+2%2C+2024/23434105.html Wed, 03 Jul 2024 16:30:00 -0400 NAVB O.00073497 http://www.streetinsider.com/Business+Wire/Navidea+Biopharmaceuticals%2C+Inc.+Announces+Results+of+Exploratory+Analysis+Completed+on+July+2%2C+2024/23434105.html <p> <i>Navidea </i><i>Biopharmaceuticals</i><i>, Inc. has completed an exploratory analysis of its Rheumatoid Arthritis Program</i> </p> <p> COLUMBUS, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the Company’s pivotal NAV3-33 clinical trial titled “Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA)” (<a target="_blank" href="http://ClinicalTrials.gov">ClinicalTrials.gov</a> Identifier: NCT05246280) the “RA Trial.” </p><p> The purpose of the exploratory analysis was to optimize the diagnostic performance in http://www.streetinsider.com/Business+Wire/Navidea+Biopharmaceuticals%2C+Inc.+Announces+Results+of+Exploratory+Analysis+Completed+on+July+2%2C+2024/23434105.html Wed, 03 Jul 2024 16:30:00 -0400 NAVB O.00073497 http://www.streetinsider.com/Press+Releases/Navidea+Biopharmaceuticals%2C+Inc.+announces+special+meeting+of+stockholders+to+be+held+July+8%2C+2024/23380910.html <p> <i>Navidea Biopharmaceucitals, Inc. will present two proposals for vote in a virtual special meeting of shareholders to be held on July 8, 2024</i> </p> <p> COLUMBUS, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024. </p><p> The purpose of the special meeting is to consider and vote upon (i) an amendment to the Company’s certificate of incorporation to allow stockholders to act by written consent, and (ii) an http://www.streetinsider.com/Press+Releases/Navidea+Biopharmaceuticals%2C+Inc.+announces+special+meeting+of+stockholders+to+be+held+July+8%2C+2024/23380910.html Thu, 20 Jun 2024 18:02:00 -0400 NAVB O.00073497 http://www.streetinsider.com/Press+Releases/Navidea+Biopharmaceuticals%2C+Inc.+announces+special+meeting+of+stockholders+to+be+held+July+8%2C+2024/23380910.html <p> <i>Navidea Biopharmaceucitals, Inc. will present two proposals for vote in a virtual special meeting of shareholders to be held on July 8, 2024</i> </p> <p> COLUMBUS, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024. </p><p> The purpose of the special meeting is to consider and vote upon (i) an amendment to the Company’s certificate of incorporation to allow stockholders to act by written consent, and (ii) an http://www.streetinsider.com/Press+Releases/Navidea+Biopharmaceuticals%2C+Inc.+announces+special+meeting+of+stockholders+to+be+held+July+8%2C+2024/23380910.html Thu, 20 Jun 2024 18:02:00 -0400 NAVB O.00073497 http://www.streetinsider.com/Business+Wire/Navidea+Biopharmaceuticals%2C+Inc.+announces+special+meeting+of+stockholders+to+be+held+July+8%2C+2024/23380910.html <p> <i>Navidea Biopharmaceucitals, Inc. will present two proposals for vote in a virtual special meeting of shareholders to be held on July 8, 2024</i> </p> <p> COLUMBUS, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024. </p><p> The purpose of the special meeting is to consider and vote upon (i) an amendment to the Company’s certificate of incorporation to allow stockholders to act by written consent, and (ii) an http://www.streetinsider.com/Business+Wire/Navidea+Biopharmaceuticals%2C+Inc.+announces+special+meeting+of+stockholders+to+be+held+July+8%2C+2024/23380910.html Thu, 20 Jun 2024 18:02:00 -0400 NAVB O.00073497 http://www.streetinsider.com/Business+Wire/Navidea+Biopharmaceuticals%2C+Inc.+announces+special+meeting+of+stockholders+to+be+held+July+8%2C+2024/23380910.html <p> <i>Navidea Biopharmaceucitals, Inc. will present two proposals for vote in a virtual special meeting of shareholders to be held on July 8, 2024</i> </p> <p> COLUMBUS, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024. </p><p> The purpose of the special meeting is to consider and vote upon (i) an amendment to the Company’s certificate of incorporation to allow stockholders to act by written consent, and (ii) an http://www.streetinsider.com/Business+Wire/Navidea+Biopharmaceuticals%2C+Inc.+announces+special+meeting+of+stockholders+to+be+held+July+8%2C+2024/23380910.html Thu, 20 Jun 2024 18:02:00 -0400 NAVB O.00073497 http://www.streetinsider.com/SEC+Filings/Form++SC+13DA+++NAVIDEA+BIOPHARMACEUTICA+++++++++++++++Filed+by%3A+Scott+John+K+Jr./22723607.html si-local-file:///var/storage/secattach/20240205/22723607.html http://www.streetinsider.com/SEC+Filings/Form++SC+13DA+++NAVIDEA+BIOPHARMACEUTICA+++++++++++++++Filed+by%3A+Scott+John+K+Jr./22723607.html Mon, 05 Feb 2024 19:53:00 -0400 NAVB O.00073497 http://www.streetinsider.com/SEC+Filings/Form++SC+13DA+++NAVIDEA+BIOPHARMACEUTICA+++++++++++++++Filed+by%3A+Scott+John+K+Jr./22723607.html si-local-file:///var/storage/secattach/20240205/22723607.html http://www.streetinsider.com/SEC+Filings/Form++SC+13DA+++NAVIDEA+BIOPHARMACEUTICA+++++++++++++++Filed+by%3A+Scott+John+K+Jr./22723607.html Mon, 05 Feb 2024 19:53:00 -0400 NAVB O.00073497 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NAVIDEA+BIOPHARMACEUTICA+++++++++++++/22705248.html si-local-file:///var/storage/secattach/20240201/22705248.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NAVIDEA+BIOPHARMACEUTICA+++++++++++++/22705248.html Thu, 01 Feb 2024 06:07:00 -0400 NAVB O.00073497 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NAVIDEA+BIOPHARMACEUTICA+++++++++++++/22705248.html si-local-file:///var/storage/secattach/20240201/22705248.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NAVIDEA+BIOPHARMACEUTICA+++++++++++++/22705248.html Thu, 01 Feb 2024 06:07:00 -0400 NAVB O.00073497 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NAVIDEA+BIOPHARMACEUTICA+++++++++++++/22705198.html si-local-file:///var/storage/secattach/20240201/22705198.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NAVIDEA+BIOPHARMACEUTICA+++++++++++++/22705198.html Thu, 01 Feb 2024 06:06:00 -0400 NAVB O.00073497 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NAVIDEA+BIOPHARMACEUTICA+++++++++++++/22705198.html si-local-file:///var/storage/secattach/20240201/22705198.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NAVIDEA+BIOPHARMACEUTICA+++++++++++++/22705198.html Thu, 01 Feb 2024 06:06:00 -0400 NAVB O.00073497